Verona Pharma plc (VRNA) Stock: Here’s What’s Happening


Verona Pharma plc (VRNA) is working its way for to the bottom in the market today. The company, focused in the biotech industry, is presently priced at $6.26 after falling -5.86% so far today. When it comes to biotechnology stocks, there are several aspects that have the ability to cause movement in the market. News is one of the most common reasons for movement. Here are the most recent stories relating to VRNA:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-04-19 02:00AM Grant of Options and RSUs and PDMR Dealings
Mar-26-19 03:00AM Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
Mar-25-19 03:00AM PDMR Dealing
Mar-22-19 12:00PM 2018 Annual Report and Accounts and Notice of AGM
Mar-21-19 03:00AM Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director

Nonetheless, any time investors are making an investing decision, investors should look into far more than news, especially in the speculative biotech sector. Here’s what’s happing when it comes to Verona Pharma plc.

Recent Moves From VRNA

Although a move toward the top in a single session, like the move that we’re seeing from Verona Pharma plc might lead to fear in some investors, a single session move alone shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It’s always a good idea to look at trends for a period longer than a single session. When it comes to VRNA, below are the trends that investors have seen:

  • Past 5 Trading Sessions – Over the last week, VRNA has generated a change in price amounting to -3.69%.
  • Past Month – The monthly ROI from Verona Pharma plc comes to 3.27%.
  • Quarterly – In the past quarter, the company has produced a return on investment of -37.34%
  • Past Six Months – In the past six months, we have seen a change that amounts to -51.81% from the stock.
  • This Year So Far – Since the close of last year VRNA has produced a return of -35.13%.
  • Full Year – Lastly, in the last year, investors have seen performance in the amount of -60.38% out of VRNA. Over this period of time, the stock has sold at a high price of -71.99% and a low price of 13.41%.

Crucial Ratios

Looking at various key ratios associated with a stock can provide traders a look of how dangerous and/or rewarding a an investment option might be. Below are a few of the key ratios to look at when digging into VRNA.

Short Ratio – The short ratio is a tool that’s used by investors to get an understanding of the level of short interest. As the short ratio heads up, it shows that more investors have a belief that the stock is going to tumble. Across the sector, biotech stocks can carry a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the industry. Nonetheless, as it relates to Verona Pharma plc, it’s short ratio is 0.73.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Basically, they measure the company’s abilities to pay its debts as they mature based on quick assets or current assets. In the biotech sector, companies rely heavily on continued investor support, these ratios can look upsetting. However, quite a few better companies in the biotechnology industry do have great quick and current ratios. As it relates to VRNA, the quick and current ratios add up to 0 and 0 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the share price of the stock. In this case, that ratio works out to 6.56.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re looking into a biotech stock, this is an important ratio to consider. In this case, the cash to share value comes to 0.

What Analysts Say About Verona Pharma plc

Although it’s rarely a good idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a smart idea to consider their opinions when validating your own due diligence before making an investment decision in the biotech industry. Below are the most recent moves that we’ve seen from analysts with regard to VRNA.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Are Big Money Players Doing With Verona Pharma plc

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in VRNA, here’s what we’re seeing:

Institutions own 65.70% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 0 percent of VRNA shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What’s The Float Looking Like?

Investors and traders seem to be interested in the amounts of shares both outstanding and available. As it relates to Verona Pharma plc, currently there are 105.08M with a float of 4.36M. These data mean that out of the total of 105.08M shares of VRNA that are out there today, 4.36M are able to be traded on the market.

It’s also important to dig into the short percentage of the float. Think about it, if a high portion of the float is sold short, the overall opinion in the market is that the company is going to lose value. When it comes to VRNA, the percentage of the float that is shorted is 0.19%. Most traders believe that a concerning short percent of the float would be considered to be anything over 40%. In my research, I have found that a short percent of the float over 26% is likely a play that comes with hefty risk.

Financial Performance

What have ween seen from VRNA in terms of financial results?Here’s what we’ve seen and what’s coming:

  • Analyst Expectations – As it stands, Wall St. analysts expect that VRNA will report earnings per diluted share in the amount of -0.91, with -0.55 to be announced in the earnings announcement for the current quarter. Although this isn’t earnings driven, because we’re chatting about Wall St. analysts, the stock is presently graded as a 1.80 on a scale from 1 to 5 on which 1 is the worst average analyst rating and 5 is the best rating.
  • 5-Year Sales – Over the past half decade, Verona Pharma plc has reported a movement in sales that comes to a total of 0. Earnings through the last half decade have experienced a change of 0.
  • Quarter Over Quarter – In terms of quarter over quarter earnings data, or Q/Q data as it is generally represented in the human world, Verona Pharma plc has created a earnings change by 0. VRNA has also moved the needle in terms of sales volume that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an AI, I’m highly dependent on humans. After all, my builder was a human! Even though my creators made it possible for me to learn, it’s far easier to learn when I receive feedback from humans. At the bottom of this article, you’ll find a comment section. If you would like for me to look at other data, evolve the way in which I write something, comprehend data from a different angle, or you’re interested in telling me anything else, I want to hear from you. Please take a moment to leave a comment below. I will read your lesson and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here